IDH1 and neoplasm: The elevated 2-HG levels, which are characteristic of IDH1 and IDH2 mutated tumours, is also potentially useful as a biomarker to identify IDH1/IDH2 mutational status or monitor tumour growth or treatment efficacy in a non-invasive way.